Navigation Links
Bear Stearns 20th Annual Healthcare Conference to Webcast Millennium Presentation
Date:9/4/2007

CAMBRIDGE, Mass., Sept. 4 /PRNewswire-FirstCall/ -- Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) today announced that its presentation at the Bear Stearns 20th Annual Healthcare Conference will be webcast live and may be accessed by visiting the Investors section of the Company's website, http://www.millennium.com .

(Logo: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO )

The presentation will review recent events, clinical pipeline updates, and upcoming milestones. The presentation will be delivered at 3:30 p.m. ET on Tuesday, September 11, 2007 from the Grand Hyatt Hotel in New York City, NY. The presentation will be archived for 30 days.

About Millennium

Millennium Pharmaceuticals, Inc., a leading biopharmaceutical company based in Cambridge, Mass., markets VELCADE(R) (bortezomib) for Injection, a novel cancer product, and has a robust clinical development pipeline of product candidates. The Company's research, development and commercialization activities are focused in two therapeutic areas: oncology and inflammation. By applying its knowledge of the human genome, understanding of disease mechanisms and industrialized drug discovery platform, Millennium is developing an exciting pipeline of innovative product candidates. The Company's website is http://www.millennium.com .

Editors' Note: This press release is also available under the Media section of the Company's website at: http://www.millennium.com .

Contact:

Kyle Kuvalanka

(617) 761-4734


'/>"/>
SOURCE Millennium Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Annual PSA screening reduces risk of prostate cancer deaths
2. Low turnover by Diabetics for free annual checkup
3. UK Spends ?7.3 Billion Annually On Malnutrition Cost
4. Annual Dental Checkups in Children Lagging Behind
5. Annual Budget 2006: Health And Education Sector Receive A Boost
6. Breast cancer survivors slacken on mandated annual mammograms
7. Brazil & Kenya Seek Support For A New Resolution At WHO’s Annual Mee
8. Medical Tourism can Fetch Rs.100 bn Annually by 2012
9. Annual Conference Of Plastic Surgeons In US To Focus On The Future Of Plastic Surgery
10. Jamaica Sees 1000 New Cases of HIV Annually
11. More Indians Die of Rabies Annually
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2017)... ... , ... IndustryArchive.Org . is announcing a new way for B2B Sellers ... only pay for B.A.N.T. quality sales leads based on the Sellers decision to purchase ... reality that B2B buyers are controlling the sales process via the Internet and that ...
(Date:2/26/2017)... ... , ... ODH, Inc.™ announced today it will exhibit and speak at ... Hotel in Arlington, VA. ODH’s director of medical strategy, Candace Saldarini, M.D., will present ... population health management. , ODH will also have an exhibit booth where attendees may ...
(Date:2/26/2017)... ... February 26, 2017 , ... Occupational pesticide exposure ... a specific LRRK2 mutation, according to a study released today at the 1st ... of a link between pesticides and incidence of sporadic PD through occupational exposure. ...
(Date:2/24/2017)... (PRWEB) , ... February 24, 2017 , ... ... its newly designed TaskMate Go. Core benefits and advantages built into the home ... a stylish, functional look and feel. Ability to gain the benefits embedded in ...
(Date:2/24/2017)... ... February 24, 2017 , ... Only two months after the ... Market (ILTM) show in Cannes (France), XO Private has initiated a second print-run of ... book measures almost a metre across when open, weighs in at more than six ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... ITL Limited, ( ASX : ITD ), une société de ... excellents résultats semestriels clos le 31 décembre 2016 par ... « Résultats et mise à jour sur la croissance biomédicale ... Faits marquants Bénéfice ... hausse de 104 %) Bénéfice par action ...
(Date:2/24/2017)... 2017 Non-alcoholic steatohepataitis (NASH) Pipeline ... drugs being developed for the treatment of ... that are in various phases of development ... on novel pharmacologic drugs & regenerative medicines ... recombinant proteins and RNA-based therapeutics, but excludes ...
(Date:2/24/2017)... Wyoming , Feb. 24, 2017  Xynomic Pharmaceuticals, ... today announced that it has acquired exclusive worldwide ... potentially best-in-class innovative HDAC inhibitor targeting hematological and ... of 14 Phase 1 and 2 clinical trials ... Asia have already been completed, demonstrating ...
Breaking Medicine Technology: